- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01489033
Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
Multicentre Phase I Randomized Double Blind Placebo Controlled Study of Subcutaneous Immunotherapy in Subjects With Allergic Rhinoconjunctivitis ± Asthma Sensitised to Phleum Pratense.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28034
- Hospital Ramón y Cajal
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must sign the informed consent form.
- Patients must be between 18 and 60 years of age.
- Patients who obtained a prick test result greater or equal to 3 mm diameter and a specific IgE greater or equal to class 2 (CAP/PHADIA) to Phleum pratense.
- Patients with seasonal allergic rhinoconjunctivitis against Phleum pratense during a minimum of 2 years prior to study participation. Although allergic rhinoconjunctivitis is the pathology under study, the inclusion of patients with mild or moderate concomitant asthma is allowed.
Patients will preferably be monosensitized to Phleum pratense. Polysensitized patients to other seasonal allergens will be accepted if sensitizations are caused by Pollens whose seasons do not overlap with Phleum pratense.
Polysensitized patients to perennial allergens will also be accepted if not clinically relevant during the study period.
- Women of childbearing potential must have a negative urine pregnancy test at Screening visit/Visit 0
- Women of childbearing potential must agree to use an appropriate contraception method during the study if they are sexually active.
Exclusion Criteria:
- Stable and continued use of medication for allergic pathology during 2 weeks prior to inclusion.
- Patients sensitised to other overlapping seasonal allergens and with specific IgE levels greater or equal to class 2 CAP/PHADIA.
- Patients who received immunotherapy in the previous 5 years for Phleum pratense or for any allergen with cross reactivity or patients that are currently receiving immunotherapy for any allergen.
- Patients with severe asthma or FEV1 lower than 60% or asthma requiring inhaled or systemic corticoid treatment at the time of study entry or within 8 weeks prior to treatment commencement.
- Patients with: immunological, cardiac, renal or hepatic illnesses or any other medical condition that the investigator deems relevant so as to interfere with the study.
- Patients with a previous history of anaphylaxis
- Patients with unstable angina
- Patients with uncontrolled hypertension
- Patients with clinically significant arrythmias
- Patients with neoplasia
- Patients with clinically relevant malformations of the upper respiratory tract.
- Other chronic or immunological disease that could interfere with the assessment of the investigation product or that could generate any additional risk for the patient
- Patients who have participated in another clinical trial within 3 month prior to enrolment.
- Patients under treatment with tricyclic antidepressives, psychotropics or beta-blockers
- Female patients who are pregnant or breast-feeding or women of childbearing potential that do not agree to use an appropriate contraception method during the study if they are sexually active, if they have not been surgical sterilised or present any other incapacity to bear
- Patient who does not attend the visits
- Patient's lack of collaboration or refusal to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A active
6 administrations and 5 weeks duration
|
Increasing doses up to a maximum dose of 500 TSU
|
Placebo Comparator: Group A placebo
6 administrations and 5 weeks duration
|
Increasing doses up to a maximum dose of 500 TSU
|
Placebo Comparator: Group B placebo
8 administrations and 7 weeks duration
|
Increasing doses up to a maximum dose of 500 TSU
|
Placebo Comparator: Group C placebo
8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.
|
Increasing doses up to a maximum dose of 500 TSU
|
Experimental: Group B active
8 administrations and 7 weeks duration
|
Increasing doses up to a maximum dose of 500 TSU
|
Experimental: Group C active
8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.
|
Increasing doses up to a maximum dose of 500 TSU
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number and seriousness of both local and systemic adverse reactions
Time Frame: From informed consent signature (V0) until the end of patient participation in the study (depending on the treatment assigned between 4 and 8 weeks )
|
From informed consent signature (V0) until the end of patient participation in the study (depending on the treatment assigned between 4 and 8 weeks )
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Immunoglobulin levels (IgE specific, IgG total and IgG4) and prick test dose response
Time Frame: Before (V0) and after treatment (depending on the treatment assigned between 4 and 8 weeks)
|
Before (V0) and after treatment (depending on the treatment assigned between 4 and 8 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Emilio Álvarez-Cuesta, Md, PhD, Hospital Universitario Ramon Y Cajal
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BIA-PHL-P1-001
- 2009-015000-26 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Rhinoconjunctivitis
-
ALK-Abelló A/SCompletedAllergic RhinoconjunctivitisSpain
-
ALK-Abelló A/SCompletedAllergic RhinoconjunctivitisSpain
-
Immunomic Therapeutics, Inc.CompletedAllergic RhinoconjunctivitisUnited States
-
ALK-Abelló A/SCompleted
-
Medical University of GrazRecruiting
-
Immunomic Therapeutics, Inc.Completed
-
University of ZurichCompletedAllergic RhinoconjunctivitisSwitzerland
-
Cytos Biotechnology AGCompletedHouse Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis
-
Cytos Biotechnology AGCompletedHouse Dust Mite Allergy | Perennial Allergic RhinoconjunctivitisSwitzerland
-
ClinNovis GmbHCompletedRhinoconjunctivitis, AllergicGermany
Clinical Trials on Subcutaneous immunotherapy with Phleum pratense pollen extract
-
Aarhus University HospitalUniversity of Aarhus; University Hospital, LinkoepingActive, not recruitingAllergic Rhinitis Due to Grass Pollen | Allergic Asthma | Allergic Conjunctivitis of Both EyesDenmark, Sweden
-
Aarhus University HospitalUniversity of Aarhus; ALK-Abelló A/S; Lundbeck FoundationCompleted
-
AbbottCompletedSeasonal Allergic RhinitisRussian Federation
-
ALK-Abelló A/SCompletedConjunctivitis | Rhinitis Allergic
-
Laboratorios Leti, S.L.CompletedAsthma | Rhinitis, Allergic, Seasonal | Conjunctivitis, AllergicSpain
-
Laboratorios Leti, S.L.CompletedSeasonal Allergic RhinitisSpain, Hungary
-
Imperial College LondonALK-Abelló A/SCompletedRhinitis, Allergic, SeasonalUnited Kingdom
-
Helsinki University Central HospitalUniversity of Helsinki; Finnish Institute of Occupational HealthCompletedRhinitis, Allergic, Seasonal
-
Stallergenes GreerTerminated
-
Imperial College LondonALK-Abelló A/SUnknownRhinitis, Allergic, SeasonalUnited Kingdom